Medindia

X

Chemotherapy-Avastin Combination Boosts Progression Free Survival Time in Ovarian Cancer Patients

by Kathy Jones on  June 3, 2012 at 10:29 PM Cancer News   - G J E 4
A new study has found that combining chemotherapy with Avastin could improve the progression-free period of patients with ovarian cancer.
 Chemotherapy-Avastin Combination Boosts Progression Free Survival Time in Ovarian Cancer Patients
Chemotherapy-Avastin Combination Boosts Progression Free Survival Time in Ovarian Cancer Patients
Advertisement

Also known as bevacizumab and marketed as Avastin by the Swiss pharmaceutical giant Roche, the drug could help women who have a resistant form of the cancer, researchers said.

Advertisement
"For the first time in platinum resistant ovarian cancer, we have been able to significantly improve progression free survival with a combination therapy," said lead study author Eric Pujade-Lauraine, a professor at Universite de Paris Descartes.

"These results are very significant because the addition of bevacizumab offers a new treatment option for the 20 percent of women who have primary platinum resistant disease, as well as those whose disease later becomes platinum-resistant."

The international, randomized phase III clinical trial included 361 patients with ovarian cancer. Some received bevacizumab in addition to standard chemotherapies; others received chemo treatments alone.

The median time of progression free survival was 6.7 months in the combination therapy group, compared to 3.4 months in chemotherapy alone group.

Previous research has shown that bevacizumab can be effective as a first and second line treatment against ovarian cancer, and future studies may shed more light on when how long to administer it.

The latest research was presented at the annual conference of the American Society of Clinical Oncology in Chicago.

Some 230,000 women are diagnosed each year worldwide with ovarian cancer. About 70 percent of patients die within five years of diagnosis.

Source: AFP
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All